ABVC BioPharma, Inc. (ABVC)

NASDAQ: ABVC · IEX Real-Time Price · USD
0.732
-0.014 (-1.88%)
Dec 9, 2022 11:25 AM EST - Market closed
-1.88%
Market Cap 24.33M
Revenue (ttm) 342,996
Net Income (ttm) -19.49M
Shares Out 32.57M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 684
Open 0.76
Previous Close 0.746
Day's Range 0.732 - 0.76
52-Week Range 0.5 - 4.26
Beta 0.28
Analysts Sell
Price Target 3.06 (+318.3%)
Earnings Date Nov 21, 2022

About ABVC

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-... [Read more]

Industry Biotechnology
Founded 2015
Employees 28
Stock Exchange NASDAQ
Ticker Symbol ABVC
Full Company Profile

Financial Performance

In 2021, ABVC BioPharma's revenue was $355,797, a decrease of -26.34% compared to the previous year's $483,045. Losses were -$12.84 million, 31.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ABVC stock is "Sell." The 12-month stock price forecast is 3.06, which is an increase of 318.32% from the latest price.

Price Target
$3.06
(318.32% upside)
Analyst Consensus: Sell
Stock Forecasts

News

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

3 weeks ago - GlobeNewsWire

ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

FREMONT, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

3 weeks ago - GlobeNewsWire

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depr...

FREMONT, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

1 month ago - GlobeNewsWire

Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Ca...

FREMONT, CA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

1 month ago - GlobeNewsWire

ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia

FREMONT, CA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

2 months ago - GlobeNewsWire

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Appr...

FREEMONT, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematolo...

2 months ago - GlobeNewsWire

ABVC Biopharma Announces Letter to Shareholders

FREMONT, CA, Sept. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...

2 months ago - GlobeNewsWire

ABVC BioPharma Selects Additional Vitargus® Phase II Study Site

New Australia Site Confirmed to Participate in the Study

3 months ago - GlobeNewsWire

ABVC Provides Oncology Pipeline Updates

Phase II Clinical Trial for Pancreatic Cancer Planned for Q2 2023

3 months ago - GlobeNewsWire

ABVC BioPharma Provides Vitargus® Update

Phase II Vitargus® Clinical Trial Receives Local Ethics Committee Approval in Thailand

3 months ago - GlobeNewsWire

ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results

FREMONT, CA, Aug. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

3 months ago - GlobeNewsWire

ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028

-- Growth to benefit ABVC's Vitargus medical device product -- FREMONT, CA, July 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical c...

4 months ago - GlobeNewsWire

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update

FREMONT, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

4 months ago - GlobeNewsWire

Zacks Places Share Value of ABVC BioPharma at $9.50

FREMONT, CA, July 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

5 months ago - GlobeNewsWire

ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation

FREMONT, CA, June 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

5 months ago - GlobeNewsWire

ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC

FREMONT, CA, June 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

5 months ago - GlobeNewsWire

ABVC BioPharma Announces Termination of Two Contracts

FREMONT, CA, June 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

5 months ago - GlobeNewsWire

ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study

FREMONT, CA, June 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

6 months ago - GlobeNewsWire

ABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners

FREMONT, CA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, ...

6 months ago - GlobeNewsWire

Prestigious Researchers to Provide Consulting Services in Connection with ABVC BioPharma's Depression Medicines

Fremont, CA, May 23, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology...

6 months ago - GlobeNewsWire

ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results

FREMONT, CA, May 16, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire --ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,...

6 months ago - GlobeNewsWire

WallachBeth Capital Announces Completion of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering

JERSEY CITY, N.J. , May 16, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced the completion of the purchase and sale of...

6 months ago - PRNewsWire

ABVC BioPharma Engages the FreeMind Group to Support Grant Funding

FREMONT, CA, May 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, ...

6 months ago - GlobeNewsWire

WallachBeth Capital Announces Pricing of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering

JERSEY CITY, N.J. , May 12, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that ABVC BioPharma, Inc. (Nasdaq: ABVC), ...

6 months ago - PRNewsWire

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated

FREMONT, CA, May 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, ...

6 months ago - GlobeNewsWire